2022-08-012023-07-312023-07-31false10892354SZ MEDICAL SERVICES LTD2024-03-08iso4217:GBPxbrli:pure108923542022-08-01108923542023-07-31108923542022-08-012023-07-31108923542021-08-01108923542022-07-31108923542021-08-012022-07-3110892354bus:SmallEntities2022-08-012023-07-3110892354bus:AuditExempt-NoAccountantsReport2022-08-012023-07-3110892354bus:AbridgedAccounts2022-08-012023-07-3110892354bus:PrivateLimitedCompanyLtd2022-08-012023-07-3110892354core:WithinOneYear2023-07-3110892354core:AfterOneYear2023-07-3110892354core:WithinOneYear2022-07-3110892354core:AfterOneYear2022-07-3110892354core:ShareCapital2023-07-3110892354core:SharePremium2023-07-3110892354core:RevaluationReserve2023-07-3110892354core:OtherReservesSubtotal2023-07-3110892354core:RetainedEarningsAccumulatedLosses2023-07-3110892354core:ShareCapital2022-07-3110892354core:SharePremium2022-07-3110892354core:RevaluationReserve2022-07-3110892354core:OtherReservesSubtotal2022-07-3110892354core:RetainedEarningsAccumulatedLosses2022-07-3110892354core:LandBuildings2023-07-3110892354core:PlantMachinery2023-07-3110892354core:Vehicles2023-07-3110892354core:FurnitureFittings2023-07-3110892354core:OfficeEquipment2023-07-3110892354core:NetGoodwill2023-07-3110892354core:IntangibleAssetsOtherThanGoodwill2023-07-3110892354core:ListedExchangeTraded2023-07-3110892354core:UnlistedNon-exchangeTraded2023-07-3110892354core:LandBuildings2022-07-3110892354core:PlantMachinery2022-07-3110892354core:Vehicles2022-07-3110892354core:FurnitureFittings2022-07-3110892354core:OfficeEquipment2022-07-3110892354core:NetGoodwill2022-07-3110892354core:IntangibleAssetsOtherThanGoodwill2022-07-3110892354core:ListedExchangeTraded2022-07-3110892354core:UnlistedNon-exchangeTraded2022-07-3110892354core:LandBuildings2022-08-012023-07-3110892354core:PlantMachinery2022-08-012023-07-3110892354core:Vehicles2022-08-012023-07-3110892354core:FurnitureFittings2022-08-012023-07-3110892354core:OfficeEquipment2022-08-012023-07-3110892354core:NetGoodwill2022-08-012023-07-3110892354core:IntangibleAssetsOtherThanGoodwill2022-08-012023-07-3110892354core:ListedExchangeTraded2022-08-012023-07-3110892354core:UnlistedNon-exchangeTraded2022-08-012023-07-3110892354core:MoreThanFiveYears2022-08-012023-07-3110892354core:Non-currentFinancialInstruments2023-07-3110892354core:Non-currentFinancialInstruments2022-07-3110892354dpl:CostSales2022-08-012023-07-3110892354dpl:DistributionCosts2022-08-012023-07-3110892354core:LandBuildings2022-08-012023-07-3110892354core:PlantMachinery2022-08-012023-07-3110892354core:Vehicles2022-08-012023-07-3110892354core:FurnitureFittings2022-08-012023-07-3110892354core:OfficeEquipment2022-08-012023-07-3110892354dpl:AdministrativeExpenses2022-08-012023-07-3110892354core:NetGoodwill2022-08-012023-07-3110892354core:IntangibleAssetsOtherThanGoodwill2022-08-012023-07-3110892354dpl:GroupUndertakings2022-08-012023-07-3110892354dpl:ParticipatingInterests2022-08-012023-07-3110892354dpl:GroupUndertakingscore:ListedExchangeTraded2022-08-012023-07-3110892354core:ListedExchangeTraded2022-08-012023-07-3110892354dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-08-012023-07-3110892354core:UnlistedNon-exchangeTraded2022-08-012023-07-3110892354dpl:CostSales2021-08-012022-07-3110892354dpl:DistributionCosts2021-08-012022-07-3110892354core:LandBuildings2021-08-012022-07-3110892354core:PlantMachinery2021-08-012022-07-3110892354core:Vehicles2021-08-012022-07-3110892354core:FurnitureFittings2021-08-012022-07-3110892354core:OfficeEquipment2021-08-012022-07-3110892354dpl:AdministrativeExpenses2021-08-012022-07-3110892354core:NetGoodwill2021-08-012022-07-3110892354core:IntangibleAssetsOtherThanGoodwill2021-08-012022-07-3110892354dpl:GroupUndertakings2021-08-012022-07-3110892354dpl:ParticipatingInterests2021-08-012022-07-3110892354dpl:GroupUndertakingscore:ListedExchangeTraded2021-08-012022-07-3110892354core:ListedExchangeTraded2021-08-012022-07-3110892354dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-08-012022-07-3110892354core:UnlistedNon-exchangeTraded2021-08-012022-07-3110892354core:NetGoodwill2023-07-3110892354core:IntangibleAssetsOtherThanGoodwill2023-07-3110892354core:LandBuildings2023-07-3110892354core:PlantMachinery2023-07-3110892354core:Vehicles2023-07-3110892354core:FurnitureFittings2023-07-3110892354core:OfficeEquipment2023-07-3110892354core:AfterOneYear2023-07-3110892354core:WithinOneYear2023-07-3110892354core:ListedExchangeTraded2023-07-3110892354core:UnlistedNon-exchangeTraded2023-07-3110892354core:ShareCapital2023-07-3110892354core:SharePremium2023-07-3110892354core:RevaluationReserve2023-07-3110892354core:OtherReservesSubtotal2023-07-3110892354core:RetainedEarningsAccumulatedLosses2023-07-3110892354core:NetGoodwill2022-07-3110892354core:IntangibleAssetsOtherThanGoodwill2022-07-3110892354core:LandBuildings2022-07-3110892354core:PlantMachinery2022-07-3110892354core:Vehicles2022-07-3110892354core:FurnitureFittings2022-07-3110892354core:OfficeEquipment2022-07-3110892354core:AfterOneYear2022-07-3110892354core:WithinOneYear2022-07-3110892354core:ListedExchangeTraded2022-07-3110892354core:UnlistedNon-exchangeTraded2022-07-3110892354core:ShareCapital2022-07-3110892354core:SharePremium2022-07-3110892354core:RevaluationReserve2022-07-3110892354core:OtherReservesSubtotal2022-07-3110892354core:RetainedEarningsAccumulatedLosses2022-07-3110892354core:NetGoodwill2021-08-0110892354core:IntangibleAssetsOtherThanGoodwill2021-08-0110892354core:LandBuildings2021-08-0110892354core:PlantMachinery2021-08-0110892354core:Vehicles2021-08-0110892354core:FurnitureFittings2021-08-0110892354core:OfficeEquipment2021-08-0110892354core:AfterOneYear2021-08-0110892354core:WithinOneYear2021-08-0110892354core:ListedExchangeTraded2021-08-0110892354core:UnlistedNon-exchangeTraded2021-08-0110892354core:ShareCapital2021-08-0110892354core:SharePremium2021-08-0110892354core:RevaluationReserve2021-08-0110892354core:OtherReservesSubtotal2021-08-0110892354core:RetainedEarningsAccumulatedLosses2021-08-0110892354core:AfterOneYear2022-08-012023-07-3110892354core:WithinOneYear2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:CostValuation2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-08-012023-07-3110892354core:Non-currentFinancialInstrumentscore:CostValuation2023-07-3110892354core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-07-3110892354core:Non-currentFinancialInstrumentscore:CostValuation2022-07-3110892354core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-07-3110892354core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-07-3110892354core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-07-3110892354core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-07-3110892354core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-07-3110892354core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-07-3110892354core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-07-3110892354core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-07-3110892354bus:Director12022-08-012023-07-31

SZ MEDICAL SERVICES LTD

Registered Number
10892354
(England and Wales)

Unaudited Financial Statements for the Year ended
31 July 2023

SZ MEDICAL SERVICES LTD
Company Information
for the year from 1 August 2022 to 31 July 2023

Director

ZABEEH ULLAH

Company Secretary

SARAH SHAHID

Registered Address

4a Hamilton House
The Avenue
London
E4 9LD

Registered Number

10892354 (England and Wales)
SZ MEDICAL SERVICES LTD
Balance Sheet as at
31 July 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets622,08841,174
22,08841,174
Current assets
Debtors77,179879
Cash at bank and on hand21,7718,128
28,9509,007
Creditors amounts falling due within one year8(17,576)(12,201)
Net current assets (liabilities)11,374(3,194)
Total assets less current liabilities33,46237,980
Net assets33,46237,980
Capital and reserves
Called up share capital11
Profit and loss account33,46137,979
Shareholders' funds33,46237,980
The financial statements were approved and authorised for issue by the Director on 8 March 2024, and are signed on its behalf by:
ZABEEH ULLAH
Director
Registered Company No. 10892354
SZ MEDICAL SERVICES LTD
Notes to the Financial Statements
for the year ended 31 July 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Principal activities
The company's principal activity during the year was that of Specialists medical practice activities.
4.Accounting policies
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Fixtures and fittings4
Office Equipment3
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
5.Employee information

20232022
Average number of employees during the year22
6.Property, plant and equipment

Total

£
Cost or valuation
At 01 August 2280,118
Additions429
At 31 July 2380,547
Depreciation and impairment
At 01 August 2238,944
Charge for year19,515
At 31 July 2358,459
Net book value
At 31 July 2322,088
At 31 July 2241,174
7.Debtors

2023

2022

££
Other debtors6,871430
Prepayments and accrued income308449
Total7,179879
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
8.Creditors within one year

2023

2022

££
Taxation and social security3,2177,196
Other creditors10,5471,192
Accrued liabilities and deferred income3,8123,813
Total17,57612,201
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.